ABVC BIOPHARMA, INC. (ABVC): Nasdaq/NYSE listing notice — ABVC BioPharma regains Nasdaq compliance after equity shortfall notice

ABVC BIOPHARMA, INC.

On April 30, 2025, Nasdaq notified ABVC that stockholders' equity of $723,959 as of April 23 failed Listing Rule 5550(b)(1).
On May 5, 2025, Nasdaq confirmed compliance after ABVC's Q1 2025 10-Q showed equity of $7,956,295, closing the matter.
The company avoided delisting by demonstrating equity above the required minimum through its quarterly filing.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

ABVC BIOPHARMA, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5550(b)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5550(b)(1)

Exact text from the filing

December 31, 2024, because its stockholders’ equity was $723,959, as of April 23, 2025, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, and it no longer comply with Listing Rule 5550(b)(1) (the “ Listing Rule ”). On May 5, 2025, the Company received a notification letter (the “ Notification Letter ”) from Nasdaq notifying the Company that the Staff has determined that based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which evidenced stockholders’ equity of $7,956,295, the Company c

View on SEC.gov

Browse all listing & compliance notices →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-040194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.